

Disrupting Biofilms to Save Limbs and Transform Wound Care

⚠️ *"Every 4 minutes, a diabetic patient in America loses a limb."*

Dr. Robert Huizinga

Interim Chief Executive Officer

✉️ rhuizinga@kanebiotech.com

🌐 www.kanebiotech.com

Forward-Looking Statements

This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, and uncertainties related to the regulatory process and general changes in economic conditions.

Investors should consult the Company's ongoing filings which are available on SEDAR for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements nor does the Company undertake to update or revise any these forward-looking statements contained herein.

Capitalization Overview

Strong ownership alignment and clean capital structure



Trading Information

Listing Symbols

TSX-V **KNE**

OTC **KNBIF**

Stock Price

\$0.04

As of Feb 2026

52-Week Range

**\$0.03 -
\$0.12**

Low - High

52W Low

52W High



Share Structure

Market Capitalization

\$7M

CAD


Shares Outstanding

181.6M

Basic



Ownership



47%

Insider Ownership

Renaud Family & Management

A Preventable Healthcare Crisis

The human and economic burden of chronic wounds is escalating



130,000

Amputations per year among
diabetic patients

🕒 One every 4 minutes



10.5M

Medicare beneficiaries suffering
from chronic wounds

Non-healing wound population



700,000

Burn-related insurance claims
annually

Includes 29,000 hospital admissions



>\$100K USD

Average cost per burn treatment

Massive economic burden



These aren't just statistics. They represent a systemic failure to treat the root cause of chronic infections.

SOURCE: CMS DATA / CDC

Malone, M., et al. (2017). The prevalence of biofilms in chronic wounds. Journal of Wound Care, 26(1):20-25; James GA, et al. (2008) Wound Repair Regen 16:37-44

Biofilms: The 1,000X Problem

Why standard treatments fail to heal chronic wounds

The Hidden Culprit

70% of burn wounds contain biofilm layers



80% of chronic wounds have established biofilms

1,000x more resistant to antibiotics than regular bacteria

i Physical or chemical disruption of biofilm before bacterial killing is needed.

What Is A Biofilm?

- 🛡️ A protective microscopic matrix created by bacteria to defend themselves
- 🚫 Reduces metabolic activity (making bacteria "invisible" to immune system)
- 🚫 Shields bacteria from antibiotics, disinfectants, and host defenses



THE TREATMENT GAP

Whether from diabetes, burns, or surgery, effective wound care **MUST** treat both bacteria **AND** biofilms. Current products often don't.

From Non-Healing to Healed

Disrupting biofilms changes outcomes for chronic wound patients



Case Study 1: 52-Year-Old Male with Diabetic Foot Ulcer

History: Multiple unsuccessful treatments prior to revyve®

Quinte Health Care



Day 1

Baseline



Day 97

Near closure



After Study End

FULLY HEALED



Case Study 2: 62-Year-Old Female with Chronic Venous Leg Ulcer

History: Recurrent since 2013. Comorbidities: Diabetes, Obesity, chronic phlebolympheidema

Pain: 10 → 0 (Week 6)



Week 1

Pain 10/10



Week 8

Pain 0/10



Week 33 (Follow-up)

SUSTAINED HEALING

\$423M - \$493M US Market Opportunity

TOTAL TAM: \$423M - \$493M

Addressing massive unmet needs across multiple care settings



\$343M Chronic Wounds

- ✓ Diabetic Foot Ulcers (DFUs)
- ✓ Venous/Arterial Leg Ulcers
- ✓ Pressure Ulcers

Care Setting Mix:



\$80-150M Inpatient Burn/Wound

- ✓ 450,000 Burn Patients/Year
- ✓ Large Surface Area Wounds
- ★ Spray Format Advantage

Hospital Burn Centers & Trauma

Market Growth Drivers



Aging Population

10,000 boomers turn 65 daily



Diabetes Epidemic

37M Americans (11.6% of US population)



Surgical Volume

Rising post-op needs



Antibiotic Crisis

Need for non-antibiotic options

Why Current Solutions Fail

Existing standards of care leave critical gaps in treatment: **revyve**[®] has the potential to be the standard of care.

 <p>Surgical Debridement</p>	 <p>Current Hydrogels</p>	 <p>Advanced Dressings</p>	 <p>Antibiotic Treatments</p>
<ul style="list-style-type: none"> ✗ Painful and traumatic procedure ✗ Expensive, requires clinic visit ✗ Biofilms reform within 24 hours <hr/> <p>✓ Removes necrotic tissue</p>	<ul style="list-style-type: none"> ✗ No biofilm disruption capability ✗ Limited antimicrobial duration ✗ Requires daily dressing changes <hr/> <p>✓ Maintains moisture balance</p>	<ul style="list-style-type: none"> ✗ Extremely high cost (\$1,000+) ✗ Limited reimbursement access ✗ Do not actively disrupt biofilms <hr/> <p>✓ Creates supportive environment</p>	<ul style="list-style-type: none"> ✗ Poor penetration into biofilms ✗ Drives antibiotic resistance ✗ Systemic side effects & dosing issues <hr/> <p>✓ Only treats planktonic bacteria</p>



The Gap in Standard of Care

No existing solution addresses: Biofilm Disruption + Sustained Antimicrobial + Ease of Use + Reimbursement

revyve®: Three Mechanisms in One

The first technology to disrupt biofilms, kill bacteria, and support healing



Biofilm Disruption

Patented **coactiv+** technology breaks down the biofilm matrix structure, exposing bacteria and reducing elevated protease activity.

✓ Physical & chemical disruption



Antimicrobial Killing

Sustained killing of bacteria for up to **7 days** without antibiotics. Effective against multi-species and resistant strains.

✓ No antibiotic resistance



Healing Support

Thermo-reversible gel supports **autolytic debridement** and maintains optimal moist wound environment for healing.

✓ Easy application & removal



THE SOLUTION






THE REVYVE® ADVANTAGE: COMPLETE CARE

- ✓ Disrupts biofilms + antimicrobial action
- ✓ Fewer dressing changes (7-day duration)
- ✓ Works with existing dressing protocols
- ✓ Non-contact spray option reduces pain

7-Day Biofilm Killing Power

Sustained activity against antibiotic-resistant pathogens without regrowth


- >4 Log Reduction (99.99%+ Kill Rate)
- Sustained 7-Day Activity (No Regrowth)
- Effective vs. Antibiotic-Resistant Strains (MRSA)
- Mature 72h Biofilm Model



Drake M., Visvalingam J., Sailer, M., Huizinga RB. (2025) Antimicrobial and Antibiofilm efficacies of a thermo-reversible Antimicrobial Wound Gel. Southern Region Burn Conference, Charleston, USA

Real World Case Series – Multiple Centers

Consistent outcomes across 9 leading wound care centers in the US and Canada



Participating Clinical Centers

- ✓ NY: Mount Sinai West
- ✓ NC: UNC (Chapel Hill)
- ✓ NC: Raleigh Foot & Ankle
- ✓ NC: Foot & Ankle Institute
- ✓ MO: St. Louis Foot & Ankle
- ✓ PA: Georgiades Surgical
- ✓ CO: The WISH Clinic
- ✓ GA: Burn & Reconstructive
- ✓ ON: Quinte Health Care

Case Series Design

- 👤 **Patient Mix:** Diabetic Foot Ulcers, Venous Leg Ulcers, Surgical Wounds
- 📄 **Protocol:** Real-world clinical practice; various dressing types
- 🕒 **Frequency:** Typical dressing changes (2-3x/week to weekly)

PRELIMINARY FINDINGS

Q4 2025 – Q1 2026

High rate of conversion from non-healing to healing transition

- ✓ **Outcomes:** Significant pain reduction & improved wound bed preparation
- ✓ **Feedback:** Positive clinician response on ease of application

📄 **Peer-reviewed publication in preparation**

Product Portfolio

Two FDA-cleared formats covering the full spectrum of wound care needs



Antimicrobial Wound Gel

Tube Format (85g/3 oz)

- ✓ **Thermo-reversible:** Liquid at cool temp, gel at body temp
- ✓ **Ease of Use:** Easy to apply, stays in place, rinses off easily
- ✓ **Indications:** DFUs, leg ulcers, pressure ulcers, surgical incisions

- ✓ FDA 510(k) Cleared
- ✓ Health Canada Approved
- ✓ Medicare Reimbursable



Target Markets

Outpatient Clinics • Podiatry • Long-Term Care • Home Health



Antimicrobial Wound Spray

Non-Aerosol Spray (5 oz)

- ✓ **Zero-Contact:** Painless application for sensitive wounds
- ✓ **Technology:** Thick gel spray adheres to vertical surfaces
- ✓ **Indications:** Large surface burns, trauma, painful wounds

- ✓ FDA 510(k) Cleared
- ✓ Health Canada Approved
- ✓ Patent Pending Delivery



Target Markets

Burn Centers • Trauma Centers • Emergency Dept • Inpatient

Competitive Differentiation

vs. Standard Hydrogels

- + Adds biofilm disruption + antimicrobial
- + 7-day duration (vs daily)

vs. Antibiotic Ointments

- + No resistance development
- + Penetrates biofilms effectively

vs. Advanced Biologics

- + Accessible pricing (vs \$1,000+)
- + No specialized training needed

Why Invest in Kane NOW: 2026 Milestones

Inflection point: Technical risk eliminated, commercial value creation ahead

1. DE-RISKED	2. PROVEN	3. COMMERCIAL	4. TIMING	5. VALUATION
<ul style="list-style-type: none"> ✓ FDA 510(k) Cleared for both products ✓ Health Canada Approved for both products ✓ Reimbursement Secured (Medicare Code) 	<ul style="list-style-type: none"> ✓ 9 Centers with consistent outcomes ✓ Biofilm Kill confirmed in lab & clinic ✓ Converting non-healing to healing 	<ul style="list-style-type: none"> ✓ Experiences Sales Team leadership in place ✓ Distribution partnerships conversations ongoing ✓ 100+ Clinic access via distributors 	<ul style="list-style-type: none"> ✓ Ageing Pop. driving wound volume ✓ Diabetes epidemic increasing ulcers ✓ Resistance tailwinds favoring non-antibiotics 	<ul style="list-style-type: none"> ✓ Undervalued vs. market potential ✓ Inflection point ahead of revenue ramp ✓ Upside potential with execution

⚡ NEAR-TERM CATALYSTS (6-12 MONTHS)

Q1 2026	Q2 2026	Q3 2026	Q4 2026
Distribution Deals	Combined Case Series Data Presentation	Hospital Contracts & Revenue Inflection	National Scale & Burn Center Wins

⚖️ Risk / Reward Profile

Risk:

Reward:

ASYMMETRIC UPSIDE POTENTIAL

Transforming Wound Care

Preventing amputations. Creating shareholder value.

The Problem	The Solution	The Market	The Inflection	The Investment
<p>130,000</p> <p>AMPUTATIONS / YEAR</p> <ul style="list-style-type: none"> Biofilms block healing 1,000X antibiotic resistance Current products fail 	<p>revyve®</p> <p>DISRUPTS & KILLS</p> <ul style="list-style-type: none"> Breaks biofilm matrix 7-Day antimicrobial FDA Cleared & Reimbursed 	<p>\$423M+ USD</p> <p>US ADDRESSABLE MARKET</p> <ul style="list-style-type: none"> Aging & Diabetes growth Resistance crisis tailwinds Cost-saving solution 	<p>NOW</p> <p>EXECUTION PHASE</p> <ul style="list-style-type: none"> Technical risk eliminated Commercial launch 2026 Distribution imminent 	<p>VALUE</p> <p>ASYMMETRIC UPSIDE</p> <ul style="list-style-type: none"> De-risked asset Undervalued potential Near-term catalysts

Three Paths to Value Creation

<p>1. Organic Growth</p> <p>Execute 2026 commercial plan to reach break-even in 2027.</p>	<p>2. Strategic Partnership</p> <p>Leverage IP for international licensing deals to generate non-dilutive capital.</p>	<p>3. Acquisition</p> <p>Attractive target for med-tech leaders seeking wound care innovation & antibiotic alternatives.</p>
--	---	---

"We are building a company, not just running a science project. We will be accountable to these milestones. We will communicate transparently. And we will create value for shareholders who believe in this mission."

Dr. Robert Huizinga
Interim CEO

Partner With Us to Transform Wound Care

Join us in preventing amputations and creating shareholder value



Dr. Robert Huizinga, PhD, RN

Interim Chief Executive Officer

✉ rhuizinga@kanebiotech.com

🌐 www.kanebiotech.com



Ray Dupuis, CPA, MBA

Chief Financial Officer

✉ rdupuis@kanebiotech.com

📠 ir@kanebiotech.com

TSX VENTURE

KNE

~\$0.04 CAD

OTC MARKETS

KNBIF

US Symbol



"We're transforming wound care—be part of this journey."